|
|
Emergent BioSolutions Announces Stock Repurchase Program
|
|
|
|
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
|
|
|
|
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
|
|
|
|
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
|
|
|
|
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
|
|
|
|
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
|
|
|
|
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
|
|
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
|
|
|
|
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
|
|
|
|
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
|
|
|
|
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
|
|
|
|
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
|
|
|
|
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
|
|
|
|
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
|
|
